UNSPSC 51282424: Pivmecillinam hydrochloride

This classification denotes a penicillin antibiotic with the molecular structure C21H33N3O5S.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 48FX7N21H2 chemically known as hydroxymethyl (2s,5r,6r)-6-(((hexahydro-1h-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate pivalate (ester) hydrochloride, but more commonly known as pivmecillinam hydrochloride, which bears US NIH Compound Identifier 115162.

European Medicines Agency schedules Pivmecillinam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03884MIG. Most nations, for tariff and trade purposes, schedule pivmecillinam hydrochloride under HS 29419000. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C.CL.

UNSPSC 51282424 Pivmecillinam hydrochloride is a Commodity code for a specific penicillin-based antibiotic pharmaceutical product. State and local governments procure this and related oral antibiotics through piggyback contracts and competitive pharmaceutical supply agreements, typically as part of broader community health or emergency preparedness initiatives. Recent solicitations under related pharmaceutical codes show state health departments and county public health agencies acquiring antibiotics and medical countermeasures through IFB and cooperative purchasing mechanisms, with contracts running 12 to 24 months and including renewal options.

Recent activity in the pharmaceutical supply space shows Illinois Department of Public Health and Seminole County, Florida as active buyers. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, with a total contract value of $2,999,999.11 over three years (12 months initial plus two one-year renewals) for antibiotic tablets supplied in bulk packages with extended shelf life. Seminole County, Florida released an IFB on June 30, 2026, for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term plus optional one-year renewal. Both procurements emphasize electronic bid submission, cost transparency, and standard contractor compliance requirements including workers' compensation insurance, drug-free workplace certification, and E-Verify authorization. State health agencies and county health departments in Florida and Illinois are the primary recent buyers, with procurement activity concentrated in the Midwest and Southeast.